Levamisole therapy as a second-line immunosuppressive agent in corticosteroid-sensitive nephrotic syndrome in children
المؤلفون المشاركون
al-Ibrahim, Alya
al-Muslim, Sulayman
al-Karraz, Salah Muhammad
al-Sadun, Dalal Mashari
al-Madani, Ahmad Jamil
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 14، العدد 2 (28 فبراير/شباط 2003)، ص ص. 153-157، 5ص.
الناشر
تاريخ النشر
2003-02-28
دولة النشر
السعودية
عدد الصفحات
5
التخصصات الرئيسية
الموضوعات
الملخص EN
To evaluate the effect of levamisole therapy combined with corticosteroid in children with nephrotic syndrome and frequent relapses (FR) or steroid dependence (SD), we studied retrospectively 24 children (18 boys and six girls) with a mean age of 32 months.
Eleven (46%) patients had FR and 13 (54%) had SD.
Levamisole was used for a mean period of 8.5 months.
The relapse rate decreased from a mean of 4 relapses / year during steroid therapy alone to 1.3 relapses / year during the combined therapy in 17 (71%) of the patients.
Remission was sustained, after discontinuing levamisole, for more than six months in 11 of the 17 responders (65%), and six patients relapsed after discontinuing levamisole.
Seven of the 24 study patients (29%) had no response to levamisole.
The seven patients who failed to respond to levamisole and the six initial responders who could not maintain remission after discontinuing the drug were treated with cyclophosphamide for 12 weeks.
Eight of these patients (61.5%) had remission sustained for a mean duration of 10 months.
The FR patients sustained remission for a longer period of time than SD patients in both groups.
Levamisole was more effective than cyclophosphamide in patients with the age of onset of the disease above 2 years (10 patients out of 11 (91%).
The side effects of levamisole and cyclophosphamide in our patients were transient and manageable.
We conclude that levamisole is a safe and effective drug if combined with corticosteroid therapy in children with nephrotic syndrome.
Further studies may be required.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Ibrahim, Alya& al-Karraz, Salah Muhammad& al-Sadun, Dalal Mashari& al-Madani, Ahmad Jamil& al-Muslim, Sulayman. 2003. Levamisole therapy as a second-line immunosuppressive agent in corticosteroid-sensitive nephrotic syndrome in children. Saudi Journal of Kidney Diseases and Transplantation،Vol. 14, no. 2, pp.153-157.
https://search.emarefa.net/detail/BIM-59986
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Ibrahim, Alya…[et al.]. Levamisole therapy as a second-line immunosuppressive agent in corticosteroid-sensitive nephrotic syndrome in children. Saudi Journal of Kidney Diseases and Transplantation Vol. 14, no. 2 (Dec. 2003), pp.153-157.
https://search.emarefa.net/detail/BIM-59986
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Ibrahim, Alya& al-Karraz, Salah Muhammad& al-Sadun, Dalal Mashari& al-Madani, Ahmad Jamil& al-Muslim, Sulayman. Levamisole therapy as a second-line immunosuppressive agent in corticosteroid-sensitive nephrotic syndrome in children. Saudi Journal of Kidney Diseases and Transplantation. 2003. Vol. 14, no. 2, pp.153-157.
https://search.emarefa.net/detail/BIM-59986
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 156-157
رقم السجل
BIM-59986
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر